In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.
The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast cancer who did not undergo completion axillary lymph node dissection.
Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results